NAAA, N-acylethanolamine acid amidase, 27163

N. diseases: 90; N. variants: 6
Disease: Thrombocytopenia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0040034
Disease: Thrombocytopenia
Thrombocytopenia 		0.050 Biomarker phenotype BEFREE In conclusion, the PLT-F demonstrated excellent performance for diagnosis of thrombocytopenia and for platelet transfusion guidance in the evaluated specimens from acute leukemia patients. 30761915 2019
CUI: C0040034
Disease: Thrombocytopenia
Thrombocytopenia 		0.050 GeneticVariation phenotype BEFREE Severe thrombocytopenia (PLT < 20 × 10<sup>9</sup>/L), identified in 31 (26.5%) patients, was associated with poor survival. 30296835 2018
CUI: C0040034
Disease: Thrombocytopenia
Thrombocytopenia 		0.050 Biomarker phenotype BEFREE The meta-analyses suggested there was a significantly higher overall response rate (OR 1.89; CI: 1.10-3.24; p = 0.02), grades of KPS (OR 2.35; CI: 1.55-3.56; p<0.01), CD3+cells (MD 10.29; CI: 8.46-12.12; p<0.01), CD4+cells (MD 7.06; CI: 5.33-8.794; p<0.01), CD4/CD8+cells (MD 0.32; CI: 0.25-0.40; p<0.01), NK+ (MD 7.20; CI: 2.02-12.37, p = 0.006), WBC (MD 1.24; CI: 0.59-1.89; p<0.01), HB (MD 14.55; CI: 7.47-21.63; p<0.01), and PLT (MD 19.05; CI: 4.29-33.81; p = 0.01), but lower severe toxicity for leukocytopenia (OR 0.37; CI: 0.17-0.80; p = 0.01), thrombocytopenia (OR 0.32; CI: 0.14-0.74; p = 0.008), gastrointestinal toxicity (OR 0.48; CI: 0.24-0.96; p = 0.04), when chemotherapy combined with SFI was compared with chemotherapy alone. 28953950 2017
CUI: C0040034
Disease: Thrombocytopenia
Thrombocytopenia 		0.050 GeneticVariation phenotype BEFREE Thrombocytopenia (PLT < 15 x 10(4)/microL) in type C cirrhosis was diagnosed in all patients with an intact spleen, 8 patients submitted to splenectomy, and in 19 non-C cirrhosis with intact spleen. 16534872 2006
CUI: C0040034
Disease: Thrombocytopenia
Thrombocytopenia 		0.050 GeneticVariation phenotype BEFREE Recombinant FVIIa (rFVIIa) has been shown to improve hemostasis in patients with thrombocytopenia and to prevent or control bleeding episodes in patients with inherited deficiencies of major PLT glycoproteins, but the mechanism of action is not well understood. 12823748 2003